Entry Detail



General Information

Database ID:exR0084396
RNA Name:WDR74
RNA Type:mRNA
Chromosome:chr11
Starnd:-
Coordinate:
Start Site(bp):62832342End Site(bp):62841809
External Links:ENSG00000133316



Disease Information

Disease Name:Fragile X Syndrome
Disease Category:Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:D005600
Type:Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA



Expression Detail

GEO ID:GSE83556
Description:Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:Disease vs Control
Case Disease Type:Fragile X Syndrome
Case Disease SubType:NA
Case Sample:Fragile X Syndrome
Control Sample:Normal
Number of Case:22
Number of Control:18
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AARS2
chr6
44298731
44313347
-
ABCA13
chr7
48171458
48647497
+
ABL2
chr1
179099330
179229684
-
AC005943.1
chr19
1578339
1605445
-
AC006064.6
chr12
6556886
6607367
-
AC011005.1
chr7
129126518
129130793
+
AC011448.1
chr19
19516227
19536076
+
AC126283.2
chr4
109713916
109801999
-
AC245033.1
chr15
82536788
82573194
-
ACO2
chr22
41469117
41528989
+
ACTG1
chr17
81509971
81523847
-
ADARB1
chr21
45073853
45226560
+
AHSA1
chr14
77457870
77469472
+
AKAP12
chr6
151239967
151358559
+
AKR1A1
chr1
45550543
45570049
+
AL136295.4
chr14
24180395
24190416
-
ALDOA
chr16
30064164
30070457
+
miRNA targets:
miRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa-miR-155-5p
chr21
25573983
25574006
+
hsa-miR-1246
chr2
176601024
176601042
-
hsa-miR-3609
chr7
98881700
98881723
+
hsa-miR-664b-5p
chrX
154768596
154768619
+
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC006064.5
chr12
6510275
6510522
+
AC007952.4
chr17
19112000
19112636
-
AC010442.1
chr5
466124
473098
-
AC114781.2
chr4
83233512
83247213
-
AC245014.3
chr1
145281116
145281462
+
AC245033.4
chr15
82533175
82540008
-
AD000090.1
chr19
35557956
35581954
+
Display:



Experiment Detail

GEO ID:GSE83556
Sample Source:Amniotic Fluid
Source Fraction:Supernatant
Platform:GPL570
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:17063
Sample treatment protocol:RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).



Reference

PMID:NA
Title:NA
Author:NA
Journal:NA
Description:NA